Market Performance - The pharmaceutical sector increased by 1.92% on July 24, 2025, outperforming the CSI 300 index by 1.21 percentage points, ranking 7th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, vaccines (+8.53%), hospitals (+3.95%), and medical research outsourcing (+3.37%) showed the best performance, while pharmaceutical distribution (+1.24%), medical consumables (+1.34%), and other biological products (+1.37%) lagged behind [1] - Top three gainers in individual stocks were Zhendong Pharmaceutical (+19.96%), Opcon Vision (+14.13%), and Maipu Medical (+10.58%); the largest decliners were Chengda Pharmaceutical (-13.12%), Renmin Tongtai (-8.95%), and Kangentai (-7.77%) [1] Industry News - The China National Medical Products Administration (NMPA) has accepted Bayer's application for the new drug BAY 2927088, an oral, reversible tyrosine kinase inhibitor (TKI) Sevabertinib, which has received breakthrough therapy designation from both the FDA and NMPA for treating adults with unresectable or metastatic non-small cell lung cancer (NSCLC) carrying HER2 activating mutations who have received prior systemic therapy [2] Company News - Heng Rui Medicine (600276) announced that its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received approval from the NMPA for the clinical trial of HRS-1893 tablets, aimed at treating heart failure with preserved ejection fraction [3] - Heng Rui Medicine (600276) also reported that its subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. received approval for the clinical trial of HRS-8179 injection, intended for the prevention of severe cerebral edema after large-area cerebral infarction [3] - Sino Medical (688108) projected a revenue of 240 million yuan for the first half of 2025, a year-on-year increase of 12.53%, with a net profit attributable to shareholders of 13.84 million yuan, up 296.54%, and a non-recurring net profit of 7.98 million yuan, up 163.35% [3] - Three Life National Health (688336) announced a collaboration with Pfizer, granting exclusive development and commercialization rights for 707 projects in mainland China, with total option and exercise fees not exceeding 150 million USD [3]

｜2025年7月24日星期四｜ NO.1 广州上半年外贸进出口额创历史同期新高 据"广东发布"微信公众号7月23日消息，今年上半年，广州市外贸进出口总额6050.5亿元，同比增长15.5%，创历史同期新高，展现出蓬 勃的发展动能与坚实韧性。 点评：这一成绩得益于市场主体活力增强、出口市场多元化、产业与业态创新等多方面因素。 点评：展会将全方位呈现影视动漫产业最新动态，助力东莞发挥"中国潮玩之都"的产业优势，促进动漫产业发展。 NO.5 深交所行情 点评：这不仅展现了深圳企业的规模实力，更揭示了其在科技创新、产业升级与全球化布局中的独特优势。 NO.3 广州警方上半年拦截挽损电诈金额6.96亿元 据南方网7月23日消息，2025年上半年，广州警方强力拦截打击"线下取现"环节，切实推进打击治理电信网络诈骗犯罪，共为群众拦截 和挽损6.96亿元，同比上升79.9%。 点评：这一成绩是警方针对犯罪手法迭代升级采取的系统性防控策略，实现了对诈骗资金的高效拦截。 NO.4 第十五届中国国际动漫博览会8月举行 据"广东发布"微信公众号7月23日消息，第十五届中国国际动漫博览会将于8月在东莞举行。展会总展览面积26400平方 ...

Core Viewpoint - The healthcare services sector experienced a 1.3% increase in value with a net capital inflow of 619 million, indicating positive market sentiment towards the industry [1] Sector Performance - The healthcare services sector saw 31 stocks rise while 13 stocks declined on the reporting day [1] - The top ten decliners in the sector included Chengda Pharmaceutical (-13.12%), Chengdu Xian Dao (-2.8%), Huakang Clean (-2.62%), and others, reflecting a mixed performance within the industry [1] Notable Stocks - Key stocks with significant movements included: - Maipu Medical: Current price 68.25, up 10.58%, with a net capital inflow of 1.77 million [1] - Medicy: Current price 64.59, up 8.83%, with a net capital inflow of 2.49 million [1] - He Yuan Biological: Current price 8.07, up 8.61%, with a net capital inflow of 4.05 million [1] - Other notable stocks included Zhaoyan New Drug, Kailai Ying, and Kanglong Chemical, each showing varying degrees of price increases and capital inflows [1]

Group 1 - The stock price of Chengda Pharmaceutical (301201.SZ) fell by 13.12% to 27.62 yuan as of the close on July 23, 2023 [1] - Chengda Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext board on January 20, 2022, with an initial public offering (IPO) of 24,174,035 shares at a price of 72.69 yuan per share [1] - The highest stock price recorded on the first day of trading was 188.00 yuan, indicating a significant decline since then, as the stock is currently in a state of "breaking" [1] Group 2 - The total amount raised from the IPO was 1,757.21 million yuan, with a net amount of 1,621.45 million yuan after deducting issuance costs [1] - The actual net fundraising exceeded the original planned amount by 1,108.17 million yuan, which was initially set at 513.28 million yuan for various projects and working capital [1] - The total issuance costs for the IPO were 135.76 million yuan, with underwriting fees amounting to 117.93 million yuan [1] Group 3 - On July 3, 2023, Chengda Pharmaceutical announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve conversion of 6 additional shares for every 10 shares held [2] - The record date for the equity distribution was set for July 6, 2023, and the ex-dividend date was July 7, 2023 [2]

Core Viewpoint - The article highlights the significant movements in various sectors of the Chinese stock market, particularly the rise in infrastructure-related stocks and the performance of the innovative drug sector, while noting a decline in the financial sector. Group 1: Infrastructure Sector - The infrastructure sector continues to rise, with notable increases in engineering machinery, civil explosives, and cement stocks [1] - Leading stocks such as China Electric Power Construction (601669) reached a limit up with over 12 million shares sealed, bringing its market value to 105.94 billion [2][3] - Other major stocks like Conch Cement, Hengli Hydraulic, and TBEA also experienced substantial gains [2] Group 2: Financial Sector - The financial sector is experiencing a pullback, with declines in banking, brokerage, diversified financials, and internet finance [4][6][7] - Specific banks such as Zheshang Bank and Industrial and Commercial Bank of China saw declines of 1.97% and 1.56%, respectively [9] - Analysts suggest that the banking sector may still have room for valuation recovery, supported by a favorable funding environment and attractive dividend yields [10] Group 3: Innovative Drug Sector - The innovative drug sector continues its upward trend, with stocks like Sailun Biotech and Chengda Pharmaceutical showing significant increases [12][15] - The sector has seen a strong performance in both A-shares and Hong Kong stocks, with several major companies announcing profitability, boosting market confidence [15] - The growth in the number and value of domestic innovative drugs entering international markets has been substantial, accounting for over half of global innovative drug transactions [15][16] Group 4: Specific Stock Movements - Upwei New Materials has seen a remarkable rise, hitting a 20% limit up for ten consecutive trading days, with a total increase of over 519% in ten trading days, bringing its market value to 19.44 billion [18][20]

Group 1 - The innovative drug sector is experiencing a resurgence, with significant stock price increases for companies such as Chengda Pharmaceutical (+14.05%) and Huisheng Pharmaceutical (+9.45%) [1][2] - The National Healthcare Security Administration (NHSA) is actively promoting high-quality development of innovative drugs through a series of meetings and discussions with industry representatives [3] - The NHSA's commitment to supporting genuine innovation and establishing a comprehensive value evaluation system for innovative drugs is expected to enhance the efficient use of healthcare resources [3] Group 2 - CITIC Securities reports that the NHSA's ongoing efforts in centralized procurement and negotiation will shift the market focus from low-price competition to quality and cost control, benefiting companies with strong quality systems and cost advantages [4] - The innovative drug sector is anticipated to receive continued policy support, with commercial insurance policies providing additional growth opportunities [4] - By 2025, the domestic innovative drug industry is expected to reach a turning point, transitioning from capital-driven to profit-driven growth, presenting dual opportunities for performance and valuation recovery [4]

Core Viewpoint - The innovative drug concept stocks have shown significant activity, with Chengdu Xian Dao and Chengda Pharmaceutical both rising over 10% following a meeting by the National Medical Insurance Administration regarding the evaluation of innovative drugs and medical devices [1] Group 1: Stock Performance - Chengdu Xian Dao and Chengda Pharmaceutical both experienced stock increases exceeding 10% [1] - Other companies such as Bai Ao Tai, Sai Sheng Pharmaceutical, Li Zhu Group, Hai Te Biological, Chen Xin Pharmaceutical, and Jian Kang Yuan saw stock rises of over 5% [1] Group 2: Regulatory Developments - The National Medical Insurance Administration held the first session of a series of discussions focused on supporting innovative drugs and medical devices [1] - The discussions centered on the topic of conducting comprehensive value assessments for innovative drugs and medical devices [1]

Group 1 - The CRO concept sector experienced a short-term surge, with Chengda Pharmaceutical (301201) rising over 10% [1] - Other companies such as Xuantai Pharmaceutical, Medisi, Saintno Biological, Sichuan Shuangma (000935), and Dezhan Health (000813) also saw increases [1] - There is a notable flow of "smart money" into the market, indicating a strategic investment trend [1]

Core Viewpoint - On July 21, a total of 23 listed companies had their restricted shares unlocked, with a total market value of approximately 5.36 billion yuan [1] Summary by Category Restricted Share Unlocking - The specific details of the restricted share unlocking include: - Shandong High Energy (000803): 1.2772 million shares from equity incentive - Yueyang Xingchang (000819): 2.1525 million shares from equity incentive - Zhangyu A (000869): 2.0357 million shares from equity incentive - Sheneng Co., Ltd. (600642): 9.7161 million shares from equity incentive - Batian Co., Ltd. (002170): 1.2 million shares from equity incentive - Wanma Co., Ltd. (002276): 2.6112 million shares from equity incentive - Chuanfa Longmang (002312): 12.5 million shares from A-share issuance - Chengda Pharmaceutical (301201): 6.15594 million shares with extended lock-up period - Maoshuo Power (002660): 8.22983 million shares from A-share issuance - Laobaixing (603883): 193.6 thousand shares from equity incentive - Zhenbaodao (603567): 726.9 thousand shares from equity incentive - Lifang Pharmaceutical (003020): 234 thousand shares from equity incentive - Triangle Defense (300775): 110.4 thousand shares from equity incentive - Yidao Information (001314): 46.26 thousand shares from equity incentive - Honghe Technology (603256): 252.65 thousand shares from equity incentive - Guomao Co., Ltd. (603915): 165.8 thousand shares from equity incentive - Arrow Home (001322): 135.28 thousand shares from equity incentive - Hongying Intelligent (001266): 18 thousand shares from equity incentive - Kangpeng Technology (688602): 4.6189 million shares - Juyi Technology (688162): 108.1 thousand shares - Xidiwei (688173): 15.4 million shares - Aike Optoelectronics (688610): 68 thousand shares - Hangcai Co., Ltd. (688563): 180 thousand shares [1]

Core Viewpoint - The announcement details the listing and circulation of certain shares prior to the initial public offering (IPO) of Chengda Pharmaceutical Co., Ltd, highlighting the changes in share structure and the commitments made by shareholders regarding share transfer restrictions [1][5][12]. Summary by Sections Initial Public Offering and Share Capital Changes - Chengda Pharmaceutical successfully completed its IPO, issuing 24,174,035 shares, resulting in a total share capital of 72,522,105 shares before the IPO and 96,696,140 shares after [1][2]. - The proportion of shares subject to trading restrictions was 77.23% of the total share capital post-IPO [1]. Changes in Share Structure Post-IPO - Following the lifting of restrictions on certain shares, the total share capital increased to 96,696,140 shares, with 23,266,070 shares being unrestricted, representing 24.06% of the total [2]. - After further share releases, the total share capital reached 154,713,824 shares, with unrestricted shares amounting to 87,193,824, accounting for 56.36% of the total [4][12]. Shareholder Commitments and Lock-up Periods - Key shareholders, including directors and investment partners, committed to not transferring their shares for 36 months post-IPO, with specific conditions for extending lock-up periods if share prices fell below the IPO price [5][6][9]. - The commitments were adhered to, and there were no violations affecting the listing of restricted shares [9][12]. Listing and Circulation of Restricted Shares - The total number of restricted shares being released for circulation was 67,520,000, which constituted 44.58% of the total share capital after excluding repurchased shares [10][12]. - The company confirmed that the released shares were not subject to any pledges or freezes [10]. Regulatory Compliance and Verification - The sponsor institution verified that all shareholder commitments were fulfilled and that the listing of restricted shares complied with relevant laws and regulations [12].